Loading…
Loading…
Vera Therapeutics NASDAQ: VERA reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The company presented the data at the American Society of Nephrology's Kidney Week meeting in Denver, alongside publication in The New England Journal of Medicine.
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composite kidney disease progression events. Favorable safety profile, and generally comparable to placebo.
Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026 Q3 2026 financial results investor webcast scheduled at 4:30 p.m.
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 16,700 shares of Class A common stock and restricted stock units (RSUs) underlying 8,350 shares of Class A common stock to five (5) new employees under the Inducement Plan.
ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vera Therapeutics Inc. (NASDAQ:VERA) shares are trading lower on Tuesday, after initially spiking higher, amid increased volatility after the company announced data from the ORIGIN 3 trial.